Document is current
Any future updates will be listed below
-
Authors
Costenbader, Karen H. https://orcid.org/0000-0002-8972-9388
DerSarkissian, Maral https://orcid.org/0000-0002-5528-6531
Chen, Yan https://orcid.org/0000-0002-5317-1909
Rabideau, Brendan https://orcid.org/0000-0003-0735-4955
Worley, Karen https://orcid.org/0009-0002-0952-8883
Man, Theo https://orcid.org/0000-0001-6382-5219
Rubin, Bernard https://orcid.org/0000-0002-9250-3865
Lim, S. Sam https://orcid.org/0000-0003-2361-0787
-
Funding
Funding for this research was provided by:
GSK (GSK Study 217537)
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 19 May 2025
First Online: 17 June 2025
Declarations
:
: Karen H. Costenbader has received grant/research support from Cabaletta Bio, Gilead, and Merck; holds stocks and shares in Neutrolis; and has worked as a paid consultant for Abbvie, Amgen, AstraZeneca, Biogen, BMS, Cabaletta Bio, GSK and Nimbus. Maral DerSarkissian, Yan Chen, Brendan Rabideau and Theo Man are employees of Analysis Group, which received research funding from GSK. Karen Worley is an employee of GSK and holds financial equities in GSK. Bernard Rubin was an employee of GSK at the time of the study, and holds financial equities in the company; his current affiliation is Progentec Diagnostics, Inc., Oklahoma City, OK, USA. S. Sam Lim received consulting fees from GSK, Accordant and AstraZeneca.
: The study was conducted in accordance with the Declaration of Helsinki 1964 and its later amendments. No direct subject contact or primary collection of individual human subject data occurred. Study results are in tabular form and presented as aggregate analyses that omit subject identification; therefore informed consent, ethics committee or IRB approval was not required. Permission from Komodo Health was obtained to access and use their database for this study.
